CEL-SCI Corp (CVM.A)

CVM.A

About

CEL-SCI Corporation (CEL-SCI) is engaged in the business of Multikine cancer therapy; New cold fill manufacturing service to the pharmaceutical industry, and ligand epitope antigen presentation System (LEAPS) technology, with two products, hemagglutinin type 1 and neuraminidase type 1 (H1N1) swine flu treatment for H1N1... (more)

Buy/Sell

» Analyst Consensus

Overall

Beta:	2.15
Market Cap (Mil.):	$77.31
Shares Outstanding (Mil.):	309.23
Dividend:	--
Yield (%):	--

Financials

	CVM.A	Industry	Sector
P/E (TTM):	--	46.63	34.30
EPS (TTM):	-0.06	--	--
ROI:	-88.90	1.55	18.43
ROE:	-160.12	2.77	19.30

Latest News about CVM.A

» More CVM.A News

Competitors

	Price	Change
Pfizer Inc. (PFE.N)	$29.04	-0.07
Johnson & Johnson (JNJ.N)	$86.82	-0.39
Novartis AG (NOVN.VX)	CHF71.25	-0.20
Merck & Co., Inc. (MRK.N)	$47.16	-0.17
Roche Holding Ltd. (ROG.VX)	CHF253.10	+2.40
Sanofi SA (SASY.PA)	€84.51	-0.30
Amgen, Inc. (AMGN.OQ)	$105.91	+0.29
Momenta Pharmaceuticals, Inc. (MNTA.OQ)	$13.39	+0.08
Seattle Genetics, Inc. (SGEN.OQ)	$34.95	-0.40

Earnings vs. Estimates

Analyst Research Reports

Report Title	Price
CEL-SCI CP (CVM) 12-months forecast Provider: Pechala's Reports	$15.00 Buy
CEL-SCI Corp: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis. Provider: Reuters Investment Profile	$20.00 Buy
Thomson Reuters Stock Report - CEL-SCI CORPORATION (CVM-A) Provider: Thomson Reuters Stock Report	$25.00 Buy
CEL-SCI Corporation (CVM) Profile and Financials, plus Biotechnology Industry Trends Analysis, Operating Ratios and Financial Averages Provider: Plunkett Research, Ltd.	$99.00 Buy
ValuEngine Detailed Valuation Report for CVM Provider: ValuEngine, Inc.	$127.00 Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Related Topics:

Edition:

U.S.
- Arabic
- Argentina
- Brazil
- Canada
- China
- France
- Germany
- India
- Italy
- Japan
- Latin America
- Mexico
- Russia
- Spain
- United Kingdom

Back to top

Reuters.com

Legal

Support & Contact

Connect with Reuters

About

Our Flagship financial information platform incorporating Reuters Insider

An ultra-low latency infrastructure for electronic trading and data distribution

A connected approach to governance, risk and compliance

Our next generation legal research platform

Our global tax workstation

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.